Rani Therapeutics
Logotype for Rani Therapeutics Holdings Inc

Rani Therapeutics (RANI) investor relations material

Rani Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Rani Therapeutics Holdings Inc
Q3 2026 earnings summary9 Nov, 2026

Executive summary

  • RT-114 Phase 1a single-dose data showed oral bioavailability above 150% versus matched subcutaneous dosing; no serious adverse events or events attributed to the capsule were reported.

  • The RaniPill platform entered the FDA Emerging Technology Program in October 2026; participation supports technical, manufacturing and regulatory discussions, but is not approval.

  • Partnerships with Chugai, ProGen and PegBio support programs in rare disease, immunology and obesity.

Financial highlights

  • Q3 contract revenue was $1.7M, all from Chugai, versus $0 in Q3 2025; 9M revenue was $5.1M versus $0.2M.

  • Q3 operating expenses rose 50.6% YoY to $10.9M; operating loss was $9.2M versus $7.3M and net loss was $8.8M versus $7.9M.

  • 9M net loss narrowed to $25.2M from $31.9M and operating loss narrowed to $26.4M from $29.8M; net loss attributable to Class A holders rose to $22.2M from $19.4M.

  • Q3 stock-based compensation was $2.2M versus $2.3M.

Outlook and guidance

  • Cash, cash equivalents and marketable securities of $45.3M at September 30, 2026 are expected to fund operations through at least end-2027 under the current operating plan.

  • Operating losses and negative operating cash flows are expected to continue; substantial additional funding will be needed for development, clinical trials and manufacturing scale-up.

  • RT-114 Phase 1a expansion data are expected by year-end 2026; Phase 1b repeat-dose data in patients with obesity are anticipated in 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Rani Therapeutics earnings date

Logotype for Rani Therapeutics Holdings Inc
Q4 202625 Mar, 2027
Rani Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Rani Therapeutics earnings date

Logotype for Rani Therapeutics Holdings Inc
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company primarily focused on the development of innovative technologies for the oral delivery of biologics. The company's flagship technology, the RaniPill capsule, represents a novel, proprietary platform designed to administer biologic drugs orally that would typically be delivered via injection. This technology aims to improve patient outcomes by making treatment more accessible and less invasive. Rani Therapeutics is exploring the potential of its platform across a range of drug substances, including peptides, proteins, and antibodies, with applications in various therapeutic areas. The company is headquartered in San Jose, California, and its shares are listed on the Nasdaq.